Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence-Based Review by the United States Food and Drug Administration

Authors: Trumbo, Paula R.; Ellwood, Kathleen C.

Source: Nutrition Reviews, Volume 64, Number 8, August 2006 , pp. 357-363(7)

Publisher: International Life Sciences Institute

Buy & download fulltext article:

Price: $37.00 plus tax (Refund Policy)

Abstract:

The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.

Keywords: CHROMIUM PICOLINATE; DIABETES; HEALTH CLAIMS; TYPE 2 DIABETES

Document Type: Research article

DOI: http://dx.doi.org/10.1301/nr.2006.aug.357-363

Publication date: 2006-08-01

More about this publication?

This journal is now published by Blackwell Publishing. Current issues of this journal are available here. Backfile content is in the process of being reloaded by Blackwell and will shortly be removed from this page and available only from the Blackwell link above.
Information for Authors
Subscribe to this Title
Translation Request
ingentaconnect is not responsible for the content or availability of external websites